ProtoKinetix raises $167.5K but has $112 cash, going‑concern flagged and dilution risk

Quick company snapshot - ProtoKinetix, Incorporated (OTCBB: PKTX)

What's happening inside the company
- Development-stage biotech focused on Anti-Freeze / Anti-Aging Glycoproteins (AAGP®).
- Company has patents and patent applications recorded as intangible assets: Intangibles (net) $473,255 as of June 30, 2025.
- No commercial product or significant revenue to date - core activity remains R&D and patent development.
- Management is actively raising capital (private placements) and issuing equity and warrants to fund operations.
- SEC filing flags "substantial doubt" about going concern; disclosure controls and procedures were evaluated as not effective.

Key facts & statistics (exact figures from 10‑Q)
- Reporting period: quarter ended June 30, 2025.
- Cash: $112 (June 30, 2025) - up from $(4,697) at 12/31/2024; cash change +$4,809 during six months.
- Total assets: $474,417; Total liabilities: $149,084; Stockholders' equity: $325,333.
- Accumulated deficit: $(48,416,903).
- Shares outstanding: 389,080,152 (as of August 13, 2025).
- Weighted average shares (six months): 381,285,401 (2025) vs 350,278,870 (2024).
- Net loss: $(188,757) for six months ended June 30, 2025 (vs $(177,103) for same period 2024).
- Six‑month expense breakdown (2025): Amortization $25,548; General & administrative $28,852; Professional fees $76,149; R&D $58,208. Total operating expenses $188,757.
- Cash flows (six months): Operating activities used $(132,027); Investing used $(30,664); Financing provided $167,500 (private placement).
- Financing activity: Issued 17,200,000 units in private placement for $167,500 cash and $4,500 services (units: 1 share + 1 warrant to purchase 1/2 share at $0.01).
- Stock options outstanding: 94,790,000; Warrants outstanding: 23,200,000 (weighted avg exercise $0.015).
- Related party balance owing: $55,700 as of June 30, 2025.
- Commitments: consulting agreements - $7,000/month and $1,500/month minimum.

Positive aspects of the income statement and financial position
- Management secured fresh cash in the period: $167,500 raised via private placement which resulted in a net increase in cash (from negative to a small positive balance).
- Operating expenses are transparent and concentrated: professional fees and R&D are the main cost drivers - consistent with an R&D-stage company.
- Amortization ($25,548) is a non‑cash charge tied to recorded patent assets, not immediate cash outflow.
- Balance sheet shows a positive book equity ($325,333) despite a large accumulated deficit - mainly driven by Additional Paid-in Capital $48,740,158, indicating ongoing investor financing/support.

Negative aspects of the income statement and financial position
- No revenue or commercial sales; net loss persists and grew slightly year-over-year for the six months ($(188,757) vs $(177,103)).
- Extremely low cash on hand ($112) and negative working capital $(147,922) - short runway without further financing.
- Heavy reliance on equity issuances; dilution risk is material given ~94.8M options and 23.2M warrants outstanding plus recent share issuances.
- Professional fees are the largest recurring cash expense ($76,149 in six months) and increased YoY - pressure on limited cash resources.
- Going concern flagged - financial statements carry no adjustments for potential failure to continue operations.
- Internal controls reported as not effective - increases disclosure and execution risk for investors.

Plain takeaways for investors and stakeholders
- ProtoKinetix (OTCBB: PKTX) remains an early-stage research company with patents and active R&D but no commercial revenue. The company is surviving on small private placements and equity-for-services issuances.
- Financial fragility is clear: cash $112, negative working capital, and ongoing losses. The next financing round(s) are essential for continued operations and to avoid material disruption.
- Upside is tied to successful R&D and IP commercialization of AAGP®. Downside is near‑term dilution, continued cash burn, and the risk the company cannot raise capital on acceptable terms.
- Monitor upcoming financing activity, dilution metrics, any revenue or licensing deals, and management's remediation of internal control weaknesses.

Source: ProtoKinetix, Incorporated Form 10‑Q for the quarter ended June 30, 2025 (filing dated August 13, 2025).